Xing Hongquan, Wu Cong, Zhang Dongdong, Zhang Xinyi
Department of Respiratory Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People's Republic of China.
Department of Pathology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People's Republic of China.
Interdiscip Cardiovasc Thorac Surg. 2024 Feb 2;38(2). doi: 10.1093/icvts/ivae007.
Our purpose is to evaluate the patterns of organ metastasis and the prognosis in lung adenosquamous carcinoma patients with organ metastasis.
We collected the data from the surveillance epidemiology and end results database, covering the period of 2000-2018. Cox regression, Kaplan-Meier and log-rank analyses were performed.
Totally, 2698 patients were enrolled, comprising 851 (31.54%) patients diagnosed with organ metastasis and 2017 (68.46%) patients without organ metastasis. Patients with distant organ metastasis show a significant decrease in median overall survival. In addition to the aforementioned factors, age over 70 years, male, main bronchus, advanced T stage, larger tumour size, absence of primary tumour surgery and lack of radiotherapy have all been identified as prognostic indicators associated with a poorer outcome. In terms of treatment options, patients with organ metastasis can benefit from chemotherapy and primary tumour surgery. Moreover, in patients with organ metastasis, those who received a combination treatment of surgery, chemotherapy and radiotherapy displayed the most favourable prognosis, with a median overall survival of 17 months.
We identified the prognostic indicators for organ metastasis in patients with lung adenosquamous carcinoma. Highly selected patients who undergo a combination treatment of surgery, chemotherapy and radiotherapy may experience the greatest survival benefit.
我们的目的是评估肺腺鳞癌伴器官转移患者的器官转移模式及预后。
我们收集了监测、流行病学和最终结果数据库中2000 - 2018年期间的数据。进行了Cox回归、Kaplan - Meier和对数秩分析。
共纳入2698例患者，其中851例（31.54%）被诊断为有器官转移，2017例（68.46%）无器官转移。远处器官转移患者的中位总生存期显著缩短。除上述因素外，年龄超过70岁、男性、主支气管、T分期较晚、肿瘤体积较大、未进行原发肿瘤手术以及未接受放疗均被确定为与较差预后相关的预后指标。在治疗选择方面，有器官转移的患者可从化疗和原发肿瘤手术中获益。此外，在有器官转移的患者中，接受手术、化疗和放疗联合治疗的患者预后最有利，中位总生存期为17个月。
我们确定了肺腺鳞癌伴器官转移患者的预后指标。经过高度筛选并接受手术、化疗和放疗联合治疗的患者可能获得最大的生存益处。
